BibTex format
@article{Evans:2025:10.1176/appi.prcp.20240128,
author = {Evans, J and Aixalà, M and Anderson, BT and Brennan, W and Bremler, R and Breeksema, JJ and Burback, L and Calder, AE and Carhart-Harris, RL and Cheung, K and Devenot, N and Gorman, I and Gre, J and Hendricks, PS and Holoyda, B and Jacobs, E and Krecké, J and Kruger, DJ and Luke, D and Maji, T and McGuire, AL and Mehtani, NJ and Mathai, DS and Nash, K and Noorani, T and Palitsky, R and Robinson, OC and Simonsson, O and Stahre, E and van, Elk M and Yaden, DB},
doi = {10.1176/appi.prcp.20240128},
journal = {Psychiatric Research and Clinical Practice},
pages = {4--8},
title = {On Minimizing Risk and Harm in the Use of Psychedelics},
url = {http://dx.doi.org/10.1176/appi.prcp.20240128},
volume = {7},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety. Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors of those harms, and the most effective way to treat those harms. They also call for better support for those experiencing post-psychedelic difficulties, including better online information, peer support groups, affordable therapy, and psychiatric consultation and medication. Finally, the authors call for better funding to create a psychedelic safety net, and suggest psychedelic philanthropists, investors and companies could commit 1% of their investment in psychedelics into supporting safety measures such as research and support services. Conclusions: The authors identify several practical steps to create a better psychedelic safety net and call for more funding to psychedelic safety measures such as research and support services. Relevance to clinical practice: The authors outline important gaps in our knowledge around the safety and risk profile of psychedelic medicines and identify practical steps forward for researchers and clinical practitioners to make this promising field safer.
AU - Evans,J
AU - Aixalà,M
AU - Anderson,BT
AU - Brennan,W
AU - Bremler,R
AU - Breeksema,JJ
AU - Burback,L
AU - Calder,AE
AU - Carhart-Harris,RL
AU - Cheung,K
AU - Devenot,N
AU - Gorman,I
AU - Gre,J
AU - Hendricks,PS
AU - Holoyda,B
AU - Jacobs,E
AU - Krecké,J
AU - Kruger,DJ
AU - Luke,D
AU - Maji,T
AU - McGuire,AL
AU - Mehtani,NJ
AU - Mathai,DS
AU - Nash,K
AU - Noorani,T
AU - Palitsky,R
AU - Robinson,OC
AU - Simonsson,O
AU - Stahre,E
AU - van,Elk M
AU - Yaden,DB
DO - 10.1176/appi.prcp.20240128
EP - 8
PY - 2025///
SP - 4
TI - On Minimizing Risk and Harm in the Use of Psychedelics
T2 - Psychiatric Research and Clinical Practice
UR - http://dx.doi.org/10.1176/appi.prcp.20240128
VL - 7
ER -
